These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 8261581

  • 1. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
    Treskes M, van der Vijgh WJ.
    Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
    [Abstract] [Full Text] [Related]

  • 2. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G, Belani CP.
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [Abstract] [Full Text] [Related]

  • 3. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
    Treskes M, Nijtmans LG, Fichtinger-Schepman AM, van der Vijgh WJ.
    Biochem Pharmacol; 1992 Mar 03; 43(5):1013-9. PubMed ID: 1313234
    [Abstract] [Full Text] [Related]

  • 4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2012 May 16; (5):CD009219. PubMed ID: 22592737
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V, Giles FJ.
    Haematologica; 1999 Nov 16; 84(11):1035-42. PubMed ID: 10553165
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
    Treskes M, Holwerda U, Klein I, Pinedo HM, van der Vijgh WJ.
    Biochem Pharmacol; 1991 Nov 06; 42(11):2125-30. PubMed ID: 1659819
    [Abstract] [Full Text] [Related]

  • 10. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
    Boven E, Verschraagen M, Hulscher TM, Erkelens CA, Hausheer FH, Pinedo HM, van der Vijgh WJ.
    Eur J Cancer; 2002 May 06; 38(8):1148-56. PubMed ID: 12008205
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative adverse effect profiles of platinum drugs.
    McKeage MJ.
    Drug Saf; 1995 Oct 06; 13(4):228-44. PubMed ID: 8573296
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
    Links M, Lewis C.
    Drugs; 1999 Mar 06; 57(3):293-308. PubMed ID: 10193684
    [Abstract] [Full Text] [Related]

  • 17. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
    Betticher DC, Anderson H, Ranson M, Meely K, Oster W, Thatcher N.
    Br J Cancer; 1995 Dec 06; 72(6):1551-5. PubMed ID: 8519676
    [Abstract] [Full Text] [Related]

  • 18. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
    van der Vijgh WJ, Korst AE.
    Eur J Cancer; 1996 Dec 06; 32A Suppl 4():S26-30. PubMed ID: 8976819
    [Abstract] [Full Text] [Related]

  • 19. Clinical pharmacokinetics of carboplatin.
    van der Vijgh WJ.
    Clin Pharmacokinet; 1991 Oct 06; 21(4):242-61. PubMed ID: 1760899
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.